The development of an ADC recognizing mouse Endo180 will be required to perform a full preclinical assessment of any normal tissue toxicity, to examine the immune engagement of the ADC, which could enhance the antitumor effect of the therapy at both the primary and metastatic sites and to determine the benefit of targeting both tumor cells and stromal CAFs. The gene discussed is MRC2; the disease is neoplasm.